Previous 10 | Next 10 |
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Lucid Diagnostics Inc. (LUCD) is expected to report for Q3 2023
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day PR Newswire EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and ...
Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum PR Newswire Lishan Aklog , M.D., Chairman &am...
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023 PR Newswire Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Nov. 1, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) ("PAVmed" or the "...
Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection PR Newswire Clinical registries are collecting real-world clinical utility and clinical validity data on EsoGuard testing in general at-risk populations and fire...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023 PR Newswire Conference Call and Webcast at 8:30AM Eastern Time NEW YORK , Oct. 31, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lu...
PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference PR Newswire NEW YORK , Sept. 21, 2023 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage...
Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection PR Newswire Multicenter observational study documents excellent concordance of EsoGuard results with subsequent medical decision-making by mu...
Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters PR Newswire Study documents 100 percent concordance between EsoGuard ® test results and subsequent medical decision-making ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Inc. Company Name:
LUCD Stock Symbol:
NASDAQ Market:
Lucid Diagnostics Inc. Website:
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing PR Newswire Firefighter #CheckYourFoodTube Precancer Testing Event organized by Mass General Brigham physicians and Boston Firefighters Local 718 IAFF NEW YORK , June...